Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial

Affiliations

• ¹ Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. Heuser.Michael@mh-hannover.de.
• ² Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
• ³ Department of Hematology and Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
• ⁴ Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
• ⁵ Hospital Universitari I Politècnic La Fe, Valencia, Spain.
• ⁶ CIBERONC, Instituto Carlos III, Madrid, Spain.
• ⁷ Juravinski Hospital At Hamilton Health Sciences, Hamilton, ON, Canada.
• ⁸ Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
• ⁹ IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
• ¹⁰ Hospital Universitario Virgen del Rocío, Instituto de Biomedicina (IbiS)/CSIC/CIBERONC), Universidad de Sevilla, Seville, Spain.
• ¹¹ Pfizer Inc, New York, NY, USA.
• ¹² University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ¹³ Georgia Cancer Center, Augusta, GA, USA.